

Methylprednisolone (pak) 4mg Oral Tablet

proven weight loss in children and adolescents with severe obesity, including those with comorbidities such as type 2 diabetes, hypertension, and dyslipidemia. The study showed that treatment with Methylprednisolone (pak) 4mg Oral Tablet led to a significant reduction in body mass index (BMI) and waist circumference, as well as improvements in metabolic parameters. These findings suggest that this medication may be a valuable tool in the management of severe pediatric obesity, particularly in cases where lifestyle interventions alone are insufficient. Further research is needed to confirm these results and to explore the long-term effects of treatment.